See more : Manulife Financial Corp (MNQFF) Income Statement Analysis – Financial Results
Complete financial analysis of Krystal Biotech, Inc. (KRYS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Krystal Biotech, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- LPKF Laser & Electronics AG (LPK.DE) Income Statement Analysis – Financial Results
- Fulgent Sun International (Holding) Co., Ltd. (9802.TW) Income Statement Analysis – Financial Results
- CM Life Sciences III Inc. (CMLTU) Income Statement Analysis – Financial Results
- SWOJAS ENERGY FOODS LTD. (SWOEF.BO) Income Statement Analysis – Financial Results
- Ashoka India Equity Investment Trust Plc (AIE.L) Income Statement Analysis – Financial Results
Krystal Biotech, Inc. (KRYS)
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 50.70M | 0.00 | 0.00 | 0.00 | 0.00 | 1.03M | 0.00 | 0.00 |
| Cost of Revenue | 3.09M | 4.05M | 2.77M | 1.85M | 974.00K | 141.00K | 23.00K | 2.00K |
| Gross Profit | 47.61M | -4.05M | -2.77M | -1.85M | -974.00K | 886.00K | -23.00K | -2.00K |
| Gross Profit Ratio | 93.90% | 0.00% | 0.00% | 0.00% | 0.00% | 86.27% | 0.00% | 0.00% |
| Research & Development | 46.43M | 42.46M | 27.88M | 17.94M | 15.62M | 7.76M | 3.21M | 741.00K |
| General & Administrative | 0.00 | 77.74M | 40.39M | 15.06M | 6.47M | 4.16M | 1.56M | 402.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 98.40M | 77.74M | 40.39M | 15.06M | 6.47M | 4.16M | 1.56M | 402.00K |
| Other Expenses | 12.50M | 25.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 157.33M | 120.20M | 68.28M | 33.00M | 22.08M | 11.92M | 4.77M | 1.14M |
| Cost & Expenses | 147.93M | 120.20M | 68.28M | 33.00M | 22.08M | 11.92M | 4.77M | 1.14M |
| Interest Income | 22.62M | 5.22M | 197.00K | 832.00K | 2.99M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 5.22M | 1.49M | 0.00 | 0.00 | 1.03M | 3.15M | 7.00K |
| Depreciation & Amortization | 5.01M | 4.05M | 2.77M | 1.85M | 974.00K | 141.00K | 23.00K | 2.00K |
| EBITDA | 17.90M | -145.20M | -65.31M | -30.32M | -18.11M | -10.75M | -4.63M | -1.14M |
| EBITDA Ratio | 35.31% | 0.00% | 0.00% | 0.00% | 0.00% | -1,146.54% | 0.00% | 0.00% |
| Operating Income | -109.73M | -145.20M | -68.28M | -33.00M | -22.08M | -11.92M | -4.77M | -1.14M |
| Operating Income Ratio | -216.43% | 0.00% | 0.00% | 0.00% | 0.00% | -1,160.27% | 0.00% | 0.00% |
| Total Other Income/Expenses | 122.62M | 5.22M | -1.30M | 832.00K | 2.99M | 1.03M | -3.15M | -7.00K |
| Income Before Tax | 12.90M | -139.98M | -69.57M | -32.17M | -19.09M | -10.89M | -7.92M | -1.15M |
| Income Before Tax Ratio | 25.44% | 0.00% | 0.00% | 0.00% | 0.00% | -1,060.27% | 0.00% | 0.00% |
| Income Tax Expense | 1.97M | 34.05M | 2.73M | 1.64M | 576.14K | -20.14K | 0.00 | 0.00 |
| Net Income | 10.93M | -139.98M | -69.57M | -32.17M | -19.09M | -10.89M | -7.92M | -1.15M |
| Net Income Ratio | 21.56% | 0.00% | 0.00% | 0.00% | 0.00% | -1,060.27% | 0.00% | 0.00% |
| EPS | 0.40 | -5.49 | -3.13 | -1.71 | -1.20 | -0.97 | -1.48 | -0.27 |
| EPS Diluted | 0.39 | -5.49 | -3.13 | -1.71 | -1.20 | -0.97 | -1.48 | -0.27 |
| Weighted Avg Shares Out | 27.15M | 25.49M | 22.20M | 18.79M | 15.90M | 11.20M | 5.36M | 4.28M |
| Weighted Avg Shares Out (Dil) | 27.75M | 25.49M | 22.20M | 18.79M | 15.90M | 11.20M | 5.36M | 4.28M |
Krystal Biotech to Present at Chardan's 6th Annual Genetic Medicines Conference
Krystal Biotech to Present at H.C. Wainwright 24th Annual Global Investment Conference
Krystal Biotech: Solid Performance, Let's Keep Holding
Can This Healthcare Stock Keep Beating the Market?
Krystal Biotech to Present at William Blair Biotech Focus Conference 2022
Krystal Biotech to Present at Goldman Sachs 43rd Annual Global Healthcare Conference
Krystal Biotech: High Potential, Buy-At-Dips Stock
Krystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the Society for Investigative Dermatology Annual Meeting
Krystal Biotech to Participate in Bank of America Merrill Lynch Global Healthcare Conference
Krystal Biotech to Present at 2022 American Academy of Dermatology Annual Meeting
Source: https://incomestatements.info
Category: Stock Reports